Skip to content

Evaluation of safety and therapeutic efficacy of siddha drug "KANDAAMALAGA ILAKAM" in the treatment of Iron deficiency anaemia.

Evaluation of safety and therapeutic efficacy of a siddha herbomineral formulation "KANDAAMALAGA ILAKAM" (Internal) in the treatment of AZHAL VELUPPU NOI (Iron deficiency anaemia) - KANDAAMALAGA ILAKAM

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014111
Enrollment
30
Registered
2018-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.

Interventions

Intervention1: kandaamalaga ilakam: 4 gms of kandaamala ilakam will be given thrice a day along with warm water for a period of 45 days Control Intervention1: Nil: Nil

Sponsors

Ayothidoss Pandithar Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hb level less than normal range, For male:7-10gms/dl(normal:13-18gms/dl),For female:7-10gms/dl(normal:11.5-16.5), patient willing to undergo blood investigation, patient who are willing to participate in study and signing in informed consent form.

Exclusion criteria

Exclusion criteria: Hypertention, presence of any associated severe systemic illness (Eg.cancer, rheumatoid), Endocrine disorder( thyroid abnormality, diabetes mellitus), severe cardiac disease,Inherited defects(sickle cell Anemia, Thalassemia, Aplastic anaemia), patient not willing to give blood sample

Design outcomes

Primary

MeasureTime frame
Primary outcome is mainly assessed by comparing the pre, mid and post treatment heamoglobin level of the study patient.Timepoint: 45 days

Secondary

MeasureTime frame
secondary outcome is assessed by comparing the following parameters, before and after the treatment, Reduction of clinical symptoms, changes in complete blood count, changes in iron supply studies.Timepoint: 45 days

Countries

India

Contacts

Public ContactDrHVetha Merlin Kumari

National Institute of Siddha

dr.kmvm@gmail.com9444249798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026